Showing results (441-450 of 480) with videos related to
Sort By:
Pageof 48
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.Science Translational Medicine|February 4, 2011
Readily available tissue-engineered vascular graftsShannon L M Dahl, Alan P Kypson, Jeffrey H Lawson, et al.The Journal of Clinical Investigation|September 4, 2013
Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza virusesNatalie J Thornburg, David P Nannemann, David L Blum, et al.The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancerDavid Loesch, F Anthony Greco, Neil N Senzer, et al.Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.Nature|November 28, 2014
An impenetrable barrier to ultrarelativistic electrons in the Van Allen radiation beltsD N Baker, A N Jaynes, V C Hoxie, et al.Viruses|December 23, 2022
In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-ProteinBruna Andersen Pereira de Jesus, Anderson Albino Gomes, Alex E Clark, et al.JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.Pageof 48